source
- Saudi FDA launches program to accelerate rare-disease drug developmentThe Saudi Food and Drug Authority (SFDA) announced a new initiative called the New Accelerator Program for Drugs in Rare Diseases (NADR). The program is designed to speed up the development, evalu…
- EU regulator withdraws Amgen's Tavneos authorization over serious trial breachesEuropean regulators have withdrawn the marketing authorization for Amgen's rare disease drug Tavneos, citing serious breaches in the pivotal clinical trial. The EMA said study staff from ChemoCent…